Table 3.

Risk ratio (RR) of progression according to each biomarker

Marker	Progression			No progression	Total
	≤ 3 months	≤ 6 months	Anytime after marker appearance
ESR1 mutation
n (%)	10 (56%)	14 (78%)	18 (100%)	0 (0%)	18 (100%)
RR (ref = non mut)	4.9 [3.0–8.0]	3.3 [2.4–4.5]	1.9 [1.7–2.0]	–
> 25% CA-15.3 increase
n (%)	12 (60%)	14 (70%)	18 (90%)	2 (10%)	20 (100%)
RR (ref = no increase)	5.9 [3.8–9.2]	3.4 [2.5–4.8]	2.0 [1.7–2.4]	–
> 100% CA-15.3 increase
n (%)	2 (50%)	2 (50%)	2 (50%)	2 (50%)	4 (100%)
RR (ref = no increase)	4.0 [1.5–11.0]	2.2 [0.8–5.8]	1.1 [0.4–2.8]	–
> 25% DNA increase
n (%)	14 (18%)	22 (29%)	45 (58%)	32 (42%)	77 (100%)
RR (ref = no increase)	1.6 [0.8–3.3]	1.1 [0.7–1.7]	0.9 [0.7–1.2]	–
> 100% DNA increase
n (%)	8 (19%)	13 (31%)	20 (48%)	22 (52%)	42 (100%)
RR (ref = no increase)	1.4 [0.7–2.7]	1.1 [0.6–1.7]	0.8 [0.6–1.2]	–